Company Encyclopedia
View More
name
PLBIO
000403.SZ
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human coagulation factor VIII, and human prothrombin complex; and freeze-dried intravenous human immunoglobulin (pH4), human fibrinogen, and intravenous hepatitis B human immunoglobulin (pH4). In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; electronic product information consultation; trading; technology application; and technical services activities. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd.
1.579 T
000403.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking30/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.06%C
    • Profit Margin23.49%A
    • Gross Margin45.34%B
  • Growth ScoreD
    • Revenue YoY-16.23%E
    • Net Profit YoY-32.45%D
    • Total Assets YoY5.77%B
    • Net Assets YoY2.48%C
  • Cash ScoreD
    • Cash Flow Margin425.63%C
    • OCF YoY-16.23%E
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreA
    • Gearing Ratio16.25%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    PLBIO: The net profit for the third quarter was 121 million yuan, a decrease of 43.74%

    PLBIO announced that its revenue for the third quarter was 632 million yuan, a decrease of 16.23%; net profit was 121 million yuan, a decrease of 43.74%. Revenue for the first three quarters was 1.618 billion yuan, a decrease of 14.40%; net profit was 357 million yuan, a decrease of 34.19%

    Zhitong·
    SZ
    000403
    +0.89%
    Zhitong·
    SZ
    000403
    +0.89%

    Open Source Securities: API companies accelerate the layout of innovative drugs, and the AI + medical layout is gradually deepening

    KaiYuan Securities released a research report indicating that the domestic API (Active Pharmaceutical Ingredient) industry is at the bottom of the cycle, with some companies actively laying out innovative drugs, expected to enter a harvest period. Meanwhile, the blood products industry is accelerating mergers and integrations, with medium to large enterprises expected to undergo mergers and reorganizations in 2025. Affected by policies, the medical services industry faces challenges, but some companies with strong brands and AI layouts are expected to recover first

    Zhitong·
    SH
    688185
    +0.64%
    HK
    06185
    -0.67%
    SZ
    000403
    +0.89%
    Zhitong·
    SH
    688185
    +0.64%
    HK
    06185
    -0.67%
    SZ
    000403
    +0.89%

    PLBIO released its performance for the first half of the year, with a net profit attributable to the parent company of 236 million yuan, a decrease of 27.89%

    According to the Zhitong Finance APP, PLBIO released its semi-annual report for 2025, showing that the company's operating revenue was 986 million yuan, a year-on-year decrease of 13.18%. The net profit attributable to shareholders of the listed company was 236 million yuan, a year-on-year decrease of 27.89%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 215 million yuan, a year-on-year decrease of 27.63%. The basic earnings per share were 0.25 yuan

    Zhitong·
    SZ
    000403
    +0.89%
    Zhitong·
    SZ
    000403
    +0.89%

    The Mystery of BTBP "Refusing" PLBIO

    First, the major shareholder takes action

    Wallstreetcn·
    SH
    600161
    +0.59%
    SZ
    000403
    +0.89%
    Wallstreetcn·
    SH
    600161
    +0.59%
    SZ
    000403
    +0.89%

    BTBP plans to abandon the acquisition of PLBIO business opportunity

    BTBP announced the abandonment of the acquisition opportunity for PLBIO, as the blood product business involved in the transaction poses a competitive conflict with its main business. The controlling shareholder China National Biological has formally notified BTBP in writing about this business opportunity based on the commitment letter to avoid competition. In the future, China National Biological will implement the acquisition of PLBIO from the perspective of overall development strategy and will make further commitments regarding the issue of competition after completion

    Zhitong·
    SZ
    000403
    +0.89%
    SH
    600161
    +0.59%
    Zhitong·
    SZ
    000403
    +0.89%
    SH
    600161
    +0.59%
    © 2025 Longbridge｜Disclaimer